
HealthEquity (HQY) Stock Forecast & Price Target
HealthEquity (HQY) Analyst Ratings
Bulls say
HealthEquity Inc has demonstrated strong financial growth, with custodial revenue increasing by 15.3% year-over-year to $159.9 million, contributing to an adjusted EBITDA margin improvement of 466 basis points, reaching 44.0%. The company’s total revenue in the third quarter rose 7.2% to $322.2 million, driven notably by custodial revenue expansion, which exceeded both internal projections and consensus estimates. Additionally, there has been a positive trend in total accounts, which grew 5.0% year-over-year to 17.280 million, reflecting increased participation in various consumer-directed benefit accounts.
Bears say
HealthEquity's stock outlook is negatively impacted by its current trading valuation, which is at 6.4 times its updated FY/26 revenue estimate, below the average valuation of its high-growth SaaS peer group at 7.6 times, indicating a potential undervaluation relative to peers. Additionally, the company faced negative results attributed to a significant $30 million one-time legal settlement in Q3/25, which may contribute to investor concerns about operational stability and financial performance. Projections for FY/27 indicate modest revenue growth of 8.3% year-over-year, slightly below prior expectations, alongside declining adjusted EBITDA expectations compared to earlier estimates, suggesting potential limitations in profitability expansion moving forward.
This aggregate rating is based on analysts' research of HealthEquity and is not a guaranteed prediction by Public.com or investment advice.
HealthEquity (HQY) Analyst Forecast & Price Prediction
Start investing in HealthEquity (HQY)
Order type
Buy in
Order amount
Est. shares
0 shares